---
schema_version: "secwatch.filing_event.v1"
accession: "0001759138-26-000025"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2026-05-14T11:06:42+00:00"
generated_at: "2026-05-14T11:11:47.071365+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q1: R&D $37.4M, cash $116.6M; $150M equity raise; rese-cel advances

## Summary
- R&D expenses $37.4M (up 29% YoY); G&A $6.9M (down 15% YoY); cash $116.6M as of March 31, 2026.
- Post-quarter $150M registered direct offering closed in May 2026, extends cash runway into mid-2027.
- Preconditioning-free rese-cel data presented at ASGCT; lowest dose showed drug-free responses in 4 PV patients.
- Registrational RESET-Myositis trial progressing with BLA submission planned for 2027; higher dose and longer-term data expected 2H26.
- Entered 10-year commercial supply agreement with Cellares for automated manufacturing of rese-cel.

## SEC filing metadata
- accession: 0001759138-26-000025
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2026-05-14T11:06:42+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/0001759138-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759138-26-000025
- JSON: https://secwatch.observer/filing/0001759138-26-000025.json
- Plain text: https://secwatch.observer/filing/0001759138-26-000025.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 14, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/0001759138-26-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.